Pharmaceutical Executive Daily: FDA's Approval of Epkinly

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.

In today’s Pharmaceutical Executive Daily, learn how Novo Nordisk is launching an introductory offer for Wegovy and Ozempic, AbbVie and Genmab gain FDA approval for Epkinly in follicular lymphoma, and Johnson & Johnson announces a $3 billion definitive agreement to acquire Halda Therapeutics.

Novo Nordisk is rolling out a new introductory pricing offer for its GLP-1 therapies Wegovy and Ozempic, aiming to expand patient access and support continued growth in the obesity and diabetes markets. The company says the initiative reflects ongoing efforts to manage demand while positioning its leading metabolic portfolio for broader uptake.

AbbVie and Genmab have received FDA approval for Epkinly as a treatment option for patients with relapsed or refractory follicular lymphoma. The decision adds a new targeted immunotherapy to the lymphoma landscape and expands the drug’s reach following prior approvals in other B-cell malignancies.

Rounding out today’s news, Johnson & Johnson has entered a $3 billion definitive agreement to acquire Halda Therapeutics. The acquisition strengthens J&J’s oncology pipeline with Halda’s targeted protein modulation platform, which is designed to develop first-in-class therapies across a range of tumor types.

Thanks for listening to Pharmaceutical Executive Daily. For more updates and in-depth analysis, visit PharmExec.com.